FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?

German Firm Plans Both US And EU Launches In 2023

 
• By Dean Rudge

Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”

Race (Panther Media GmbH/Alamy Stock Photo)
Who will get over the line first? • Source: Shutterstock (Panther Media GmbH / Alamy Stock/Alamy Stock Photo)

Fresenius Kabi has thrown down the gauntlet in the race to launch a biosimilar to Roche’s Actemra (tocilizumab) blockbuster interleukin inhibitor for the treatment of inflammatory diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products